Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Halneuron
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2023
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Halneuron
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2023
Lead Product(s) : Tetrodotoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Seviprotimut-L stimulates humoral and cellular immune response, is in clinical development as a potential adjuvant treatment for patients 60 years and younger with Stage IIB or IIC melanoma.
Product Name : POL-103A
Product Type : Vaccine
Upfront Cash : Inapplicable
November 01, 2022
Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L
Details : U.S. Food and Drug Administration (FDA) has granted Polynoma's application for Fast Track designation of seviprotimut-L, its melanoma cancer vaccine for the adjuvant treatment of stage IIB/IIC melanoma patients post-resection to improve recurrence-free s...
Product Name : POL-103A
Product Type : Vaccine
Upfront Cash : Inapplicable
June 23, 2020
Details : Study data show a durable recurrence-free survival clinical benefit in patients with localized melanoma, supporting the potential use of seviprotimut-L as an adjuvant treatment.
Product Name : POL-103A
Product Type : Vaccine
Upfront Cash : Inapplicable
May 13, 2020